Illumina launches fast, flexible whole-genome sequencing solution for cancer residual disease detection

Illumina has introduced a new whole-genome sequencing (WGS) solution for molecular residual disease (MRD) research, enabling faster and more flexible detection of cancer residuals during and after treatment. This distributed kit supports both solid tumor fingerprinting and blood cancer genomic profiling, with high sensitivity and a workflow that can be completed in as fast as 5 days. Early access partners like Mayo Clinic report strong performance, and Illumina plans a global launch next year, aiming to make MRD detection more accessible and scalable in clinical research. The solution leverages the advanced NovaSeq X platform and DRAGEN MRD analysis for high accuracy and speed, supporting the growing precision oncology market.